Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 27, 2017
Pharmacy Choice - News - Pharmaceutical Development - March 27, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/27/17 - "Hypotensive Lipid-Containing Biodegradable Intraocular Implants and Related Implants" in Patent Application Approval Process (USPTO 20170065612)
By a News Reporter-Staff News Editor at Clinical Trials Week A patent application by the inventor Hughes, Patrick M., filed on November 21, 2016, was made available online on March 16, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned to a company or instit
3/27/17 - Active Implants LLC Secures First Tranche of a $40 Million Equity Financing
By a News Reporter-Staff News Editor at Clinical Trials Week Active Implants, LLC, a company that develops orthopedic implant solutions, announced that it completed the first $10 million tranche of a $40 million Class D Units financing. The financing is to be comprised of $30 million from first-time investor LS Health Science Partners, L.P., with
3/27/17 - Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne
DUBLIN and BOSTON, March 27, 2017/ PRNewswire/ Allergan plc,, a leading global pharmaceutical company and Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced that two Phase 3 trials of sarecycline for the treatment of moder
3/27/17 - Allergan, Paratek Report Positive Results From Two Phase 3 Trials Of Sarecycline
WASHINGTON- Allergan plc and Paratek Pharmaceuticals Inc. announced that two Phase 3 trials of sarecycline for the treatment of moderate to severe acne met their 12 week primary efficacy endpoints. Based on these data, Allergan plans to file a New Drug Application to the U.S. Food& Drug Administration in the second half of this year. said David Nic
3/27/17 - Altasciences Clinical Research Companies Recognized for Leadership
By a News Reporter-Staff News Editor at Clinical Trials Week Altasciences Clinical Research proudly announces that its companies, Algorithme Pharma and Vince& Associates Clinical Research, have each been awarded multiple 2017 CRO Leadership Awards. This is the fourth consecutive year that Algorithme Pharma has been recognized by the industry.
3/27/17 - APEIRON Biologics Receives Green Light for Marketing Approval of a Neuroblastoma Immunotherapy in the European Union
APEIRON Biologics AG today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of dinutuximab beta for immunotherapy of high risk neuroblastoma. The development was extended to multiple clinical trials across Europe and abroad, performed by the SIOPEN
3/27/17 - ArQule Announces Top-Line Results of Phase 3 Clinical Study of Tivantinib in Hepatocellular Carcinoma in Japan
ArQule, Inc. today reported that its partner, Kyowa Hakko Kirin, announced top-line results of the JET-HCC Phase 3 trial of tivantinib in Japan, and that the trial did not meet its primary endpoint of progression free survival. I would like to thank our partner, Kyowa Hakko Kirin, and all the participants in their study, said Paolo Pucci, Chi
3/27/17 - Asana BioSciences Announces FDA Acceptance of the IND Application for its Novel SYK-JAK Inhibitor for Evaluation in Atopic Dermatitis
By a News Reporter-Staff News Editor at Clinical Trials Week Asana BioSciences, LLC, a clinical stage biopharmaceutical company, announced that the FDA has accepted the IND application for ASN002, a novel dual SYK-JAK inhibitor, for atopic dermatitis. "We are extremely pleased with the efficient execution of our strategy to work on clinically va
3/27/17 - AstraZeneca plc (ADR) (NYSE:AZN) Tagrisso Wins Approval In China
Tragrisso, a drug developed by AstraZeneca plc (ADR) (NYSE:AZN), has been granted approval in China. The treatment is designed to assist patients who are suffering from cancer and who have particular genetic mutations that are commonly found in the world's most populous country. China's approval of Tagrisso not only boosts the prospects of Astr
3/27/17 - Bharat Book Bureau: Breakthrough Therapies: Market
The global market for breakthrough therapy designation drugs should reach $99.2 billion by 2022 from $48.8 billion in 2017 at a compound annual growth rate of 15.2%, from 2017 to 2022.. -An overview of the global markets for breakthrough therapies, their dynamics, and investment opportunities. In July 2012, the FDA introduced a new breakthrough the
3/27/17 - BIOPHYTISopens the first clinical centers in Europe and starts the recruitment of sarcopenic patients for SARA-OBS study
BIOPHYTIS, a biotechnology company specialized in the development of drug candidates to treat ageing diseases, announced that the first clinical centers leading the observational study SARA-OBS have opened in Europe and started the recruitment of patients. The first clinical centers have opened and started the screening of patients with sarcopeni
3/27/17 - Bridge Medicines Appoints William J. Polvino, M.D., As Chief Executive Officer
Bridge Medicines, launched by Memorial Sloan Kettering Cancer Center, The Rockefeller University, Weill Cornell Medicine and Takeda Pharmaceutical Company Ltd., in partnership with Deerfield Management and Bay City Capital, is a groundbreaking initiative that extends the work of the independent, non-profit Tri-Institutional Therapeutics Discovery..
3/27/17 - Celltex autologous stem cell case study published in Stem Cells and Development demonstrates favorable response in pediatric patients
By a News Reporter-Staff News Editor at Clinical Trials Week Houston- based biotechnology company HYPERLINK " http://www.celltexbank.com/"\ nCelltex Therapeutics Corporation announces that Stem Cells and Development has published "HYPERLINK" http://online.liebertpub.com/doi/abs/10. 1089/ scd.2016.0196 "\ nAutologous Adipose Stem Cell Therapy for.
3/27/17 - CytoSorbents Announces CytoSorb Partnership with Dr. Reddy's Laboratories
By a News Reporter-Staff News Editor at Clinical Trials Week HYPERLINK " http://www.cytosorbents.com/"\ n CytoSorbents Corporation, manufacturer of the HYPERLINK " http://www.cytosorb.com/"\ nCytoSorb extracorporeal blood purification therapy that reduces excessive levels of inflammatory mediators in critically-ill and cardiac surgery patients
3/27/17 - CytoSorbents REFRESH I Trial Abstract Selected for Podium Presentation at the American Association for Thoracic Surgery Centennial Conference
CytoSorbents Corporation, a critical care immunotherapy leader commercializing its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced the selection of its REFRESH I cardiac surgery "Late-Breaking Clinical Trial" abstract for podium presentation at the..
3/27/17 - Data on Central Venous Catheter Detailed by Researchers at Isfahan University of Medical Sciences (Inserting central venous catheter in emergency...
Data on Central Venous Catheter Detailed by Researchers at Isfahan University of Medical Sciences. According to news reporting originating in Isfahan, Iran, by NewsRx journalists, research stated, "The current study was designed to compare the complications and adverse effects of central venous catheter insertion under ultrasound guidance in patien
3/27/17 - Dinutuximab beta receives positive recommendation for the treatment of high-risk neuroblastoma in Europe
EUSA Pharma today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion in favour of marketing authorization for the antibody ch14.18/CHO, Dinutuximab beta, for the treatment of children aged 12 months and above, who have previously received induction chemotherapy and achieved at
3/27/17 - Drug combination delivered by nanoparticles may help in melanoma treatment
By a News Reporter-Staff News Editor at Clinical Trials Week The first of a new class of medication that delivers a combination of drugs by nanoparticle may keep melanoma from becoming resistant to treatment, according to Penn State College of Medicine researchers. CelePlum-777 combines a special ratio of the drugs Celecoxib, an anti-inflammatory
3/27/17 - ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced positive topline results from its Phase 2 b clinical study evaluating its product candidate, eryaspase, in combination with chemotherapy for the treatment of...
3/27/17 - EUSA Pharma and Apeiron Biologics Receive Positive CHMP Opinion for dinutuximab beta for the Treatment of High-risk neuroblastoma in Europe
EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care, and Apeiron Biologics today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of dinutuximab beta for use in the treatment of high-risk...
3/27/17 - FDA Grants Priority Review for Eagle Pharmaceuticals Ryanodex NDA for the Treatment of Exertional Heat Stroke
Eagle Pharmaceuticals announced today that their 505 New Drug Application for Ryanodex for the treatment of exertional heat stroke has been accepted for filing and granted a priority review designation by the U.S. Food and Drug Administration. The FDA grants priority review to medicines that may offer major advances in care or provide a treatmen
3/27/17 - Findings from University of Michigan Provide New Insights into Post-Trial Research (Anatomical patterns of recurrence following biochemical relapse...
Findings from University of Michigan Provide New Insights into Post-Trial Research. By a News Reporter-Staff News Editor at Clinical Trials Week A new study on Clinical Trials and Studies- Post-Trial Research is now available. The news correspondents obtained a quote from the research from the University of Michigan, "Anatomical recurrence patter
3/27/17 - Findings in the Area of Alcoholic Hepatitis Reported from Queen Mary Hospital (Liver transplantation for severe alcoholic hepatitis-The CON view)
By a News Reporter-Staff News Editor at Clinical Trials Week Investigators discuss new findings in Alcohol-Induced Diseases and Conditions- Alcoholic Hepatitis. According to news reporting out of Hong Kong, People's Republic of China, by NewsRx editors, the research stated, "In patients with severe alcoholic hepatitis who have failed medical ther
3/27/17 - Findings on Monoclonal Antibodies Reported by R. Wanchoo et al (Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review)
By a News Reporter-Staff News Editor at Clinical Trials Week Investigators publish new report on Drugs and Therapies- Monoclonal Antibodies. According to news reporting out of Great Neck, New York, by NewsRx editors, research stated, "Cancer immunotherapy, such as anti-cytotoxic T-lymphocyte-associated protein 4 and anti-programmed death 1, has..
3/27/17 - First dedicated outcome trials of empagliflozin in chronic heart failure initiated
By a News Reporter-Staff News Editor at Diabetes Week- Boehringer Ingelheim and Eli Lilly and Company announced that the EMPEROR HF clinical trial program was initiated. It is the leading cause of hospitalizations in the United States and Europe, with more than 1 million admissions annually for heart failure as the primary diagnosis. We need to e
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415